Practical Implications e104 Author Information e113 Web Exclusive www.ajpblive.com

Advanced Oral Contraceptive Regimens and Their Management

Mohd Aftab Alam, PhD; Raisuddin Ali, PhD; Fahad Ibrahim Al-Jenoobi, PhD; and Abdullah M. Al-mohizea, PhD

ince the 1960s, oral contraceptives have been prescribed to fertile women for preventing unwanted pregnancy. Numerous contraceptive methods and products can be used. Some of them are oral pills, intrauterine devices, transdermal patches, implants, surgical procedures, condoms, diaphragms, cervical caps, injections, vaginal rings, and vaginal spermicides. 1-3 The order of efficacy of contraceptive methods is presented in the Figure. 4 Large numbers of oral contraceptive products are available in the market, varying in dose strength, regimen, packaging, and hormone combinations. In the present review, we elaborate mainly on oral contraceptive pills (OCPs)—their dosage regimens, dosage strengths, compositions, and guidelines to manage missed pills—as well as emergency oral contraceptives.

Oral contraceptive pills are among the preferred contraceptive methods because they are easy to take, there is no pleasure interruption, no surgical procedure is required, there is no device-related discomfort, they can be discontinued easily if the couple is planning for pregnancy, and the method is highly effective when taken properly according to the regimen. Success of OCPs is almost 99% when taken regularly according to recommended regimens.² Compliance is the only major issue associated with OCPs and is considered to be responsible for cases of failure. Clinicians can play an important role in improving compliance by proper counseling of consumers about side effects, dose routine, and missed pill management, and can suggest backup plans in case of missed pills.⁵⁻⁸ Various packaging and other methods such as wallet pill cards specifying days of the pills (Ovcon-50), colored pills (Ortho-Tri-Cyclen), shaped pills (Estrostep Fe), dial-pack dispensers (Ortho-Novum, Ortho-Cyclen), and click-case dispensers (Lybrel) have been developed to improve compliance.

Selection of the right contraceptive method/product requires making decisions, because the choice varies from person to person.9 Several factors play important roles in the selection of contraceptives. A few of these factors are safety and side effects, health risks, simplicity of the method, user's

ABSTRACT

Contraceptive pill regimens have gone through numerous changes and modifications to improve safety, compliance, and tolerability. Several generations of progestins were introduced, and their doses were adjusted over time. Four dosing regimens (monophasic, biphasic, triphasic and quadriphasic) have been introduced. These dosing regimens provide different hormonal doses at different stages of menstrual cycle. The 28-day cyclic (21 + 7) regimens are preferred because they result in better compliance than 21-day regimens. In the present review, we comprehensively describe the development of contraceptive pills, contraceptive doses, dose regimens, cyclic regimens, extended-cycle contraceptive pills, selection criteria of contraceptives, and emergency contraceptive pills. We also provide the FDA's guidelines for managing missed contraceptive pills to assist users in taking them safely and to avoid contraceptive failure. In conclusion, the literature suggests that the success of combined oral contraceptive pills depends on regular intake according to a prescribed routine.

Am J Pharm Benefits. 2014;6(4):e103-e114

PRACTICAL IMPLICATIONS

Contraceptive pill regimens have gone through numerous changes and modifications to improve safety, compliance, and tolerability.

- Contraceptive pills should be taken according to a regular routine, and dose regimens should be followed strictly.
- Missed pills should be managed according to recommended guidelines.
- User-friendly packaging, which can improve compliance, is preferred.
- Nonhormonal contraceptive backup plans should be used for prescribed days when pills are missed.

compliance, user's experience, protection against sexually transmitted disease, success rate, pharmacoeconomic concerns, frequency of intercourse, lifestyle, age, product availability and access, sociocultural convictions, overthe-counter versus prescription products, cost, effects on regular periods, advice from partner, friends, or health professionals, advertising, interruption of pleasure, duration of contraception desired, duration of contraceptive effectiveness, mode of contraception (eg, reversible or irreversible), and so forth. Mishell and colleagues updated the guidelines for oral contraceptive selection and recommended oral contraceptives as a first choice unless the consumer has some contraindication or intolerable side effects, or difficulty in taking pills regularly.

LOW-DOSE AND ULTRA-LOW-DOSE ORAL CONTRACEPTIVES

The doses of contraceptives have been adjusted many times to reduce side effects. The doses of progestin or estrogen or both were reduced or shuffled. Combined oral contraceptive pills (COCPs) with higher estrogen content were discontinued (eg, Enovid, Ortho-Novum 10/21, Demulen 1/50, Ovcon-50, Preven). Estrogen content of currently available COCPs varies from 10 µg to 50 µg. The products containing 10 µg of estrogen are considered ultra–low- dose oral contraceptives (eg, Lo Loestrin Fe). Most of the marketed COCPs contain 20 µg to 35 µg of estrogen such as ethinyl estradiol (eg, Loestrin Fe 1/20, Loestrin Fe 1.5/30, Ovcon-35) (Table). The lower amount of ethinyl estradiol reduces the risk of thrombotic incidents and improves the safety for consumers.^{17,18}

MONOPHASIC, BIPHASIC, TRIPHASIC, AND QUADRIPHASIC ORAL CONTRACEPTIVES

In addition to dose reduction, changing the dose regimen was another attempt to reduce the side effects caused

by COCPs.^{19,20} Since the 1960s, many dose regimens (monophasic, biphasic, triphasic, quadriphasic, and extended cycle) have been approved by the FDA as COCPs. There is no strong evidence to support the superiority of multiphasic oral contraceptives regimens (biphasic, triphasic, or quadriphasic) over monophasic regimens for birth control, and bleeding patterns.²¹⁻²³ Monophasic regimens (eg, Modicon-28, Yasmin, Desogen)provide a fixed hormone dose throughout the cycle. Most of the marketed COCP products are still monophasic (Table). Biphasic (eg, Lo Loestrin Fe), triphasic (eg, Ortho Tri-Cyclen, Ortho Tri-Cyclen-28, Ortho Tri-Cyclen-21, Ortho

Tri-Cyclen Lo, Cyclessa, Estrostep Fe, Tri-Norinyl 28-Day, Ortho-Novum 7/7/7-28), and quadriphasic (eg, Natazia) regimens provide 2, 3, and 4 different doses, respectively, of estrogen, progestin, or both in a complete menstrual cycle. These regimens are designed to mimic the normal hormonal activity at different phases in the cycle to provide a better response along with fewer side effects, although they are quite complex and may pose compliance issues.

A trend of providing supplements with contraceptive regimens began in 1970s. The 7 inert pills of 28- and 91-days regimens are loaded with supplements, though these supplements do not prove any contraceptive potency. ²⁴⁻²⁶ Examples of such products are Loestrin 24 Fe (ferrous fumarate), Norquest Fe (ferrous fumarate), Beyaz (levomefolate calcium), Safyral (levomefolate calcium), and Estrostep Fe (ferrous fumarate).

EXTENDED-CYCLE CONTRACEPTIVES

The extended-cycle contraceptives (eg, COCPs, implants, transdermal patch, vaginal rings) are used to prevent pregnancy as well as monthly bleeding by providing a continuous supply of hormones. Seasonique and Seasonale are COCPs approved for a 91-day extended cycle. The extended-cycle contraceptives are intended for women who want to avoid monthly bleeding because of travel, sports, vacations, parties, honeymoon, busy schedule, and so forth. Extended-cycle contraceptive regimens decrease the hormone-free period and reduce the scheduled bleeding episodes, as well as withdrawal symptoms such menstrual pain, headache, breast tenderness, bloating, cramping, and hypermenorrhea.^{18,27,28}

EMERGENCY CONTRACEPTIVES

Most contraceptives are used before (eg, COCPs, implants, vaginal rings) or during (eg, condoms,




Figure 1. Order of Contraceptive Methods' Efficacy (from left to right)

diaphragms) intercourse. Emergency contraceptives (EMCs) are used after unprotected sex or when a contraceptive method has failed.³¹ Emergency contraceptives also are called "postcoital contraceptives" or "morningafter pills." Emergency contraceptives are used in cases of failed coitus interruptus, failed contraceptive methods (eg, diaphragm slipped out of place, breakage or misuse of condom during intercourse), sexual assault, consecutive missed contraceptive pills, and when no other contraceptive has been used. Emergency contraceptives act by preventing or delaying ovulation.32,33 Sometimes, if the egg is fertilized by sperm, EMCs may prevent its implantation in the uterus wall.³³ Emergency contraceptives can be useful for the victims of sexual assault because undesired pregnancy can be avoided by taking the EMC pills within the recommended time period. Emergency contraceptive regimens recommend taking the pills as soon as possible within 3 to 5 days after unprotected intercourse.34 In June 1996, the FDA Maternal and Reproductive Health Drugs Advisory Committee found that the use of EMCs pills within 72 hours of unprotected

intercourse is safe and effective. The EMCs will also open a safe gate for women who are having intercourse less frequently (fewer than 4 times a month).35 In such cases, unnecessary long- term exposure to combined contraceptives and extended contraceptive cycles can be avoided. Emergency contraceptives contain progestin in combination with estrogen (Yuzpe), progestin alone (Plan B), or antiprogestin (Ella). The Yuzpe method was the subject of a landmark study in the history of emergency contraception.³⁶ With the Yuzpe method, the combination of estrogen and progestin is used for emergency contraception, and a series of 4 contraceptive pills is taken.37-39 The progestin-only EMCs were introduced as Plan B One-Step (single dose, 1.5 mg of levonorgestrel) and Plan B (2 doses, 0.75 mg of levonorgestrel).34 Different EMC pills have different dosage regimens. The dose of Plan B One-Step should be taken within 72 hours, whereas in the case of Plan B the first dose should be taken within 72 hours and the second dose within 12 hours after the first dose. Plan B is available without a prescription, but the Yuzpe method requires a prescription. Ella

■ Alam · Ali · Al-Jenoobi · Al-mohizea

Table. List of Oral Contraceptive Pills Marketed in United States

No.	Brand Company Approval Year	Regimen	Product Strength
1.	NORINYL 1+50 28-DAY Watson Labs	28 days = 21 days active pills + 7 days inert pills	Mestranol; Norethindrone 0.05 mg; 1 mg Tablet; Oral-28
	nts: lactose, magnesium stearate, po ablets: FD&C Yellow No. 6, lactose, m	ovidone, and starch. icrocrystalline cellulose, and magnesium stearate.	
2.	MICRONOR Janssen Pharmaceuticals	28 active pills, 1 pill daily.	Norethindrone 0.35 mg Tablet; Oral-28
Excipie	nts: Corn starch, D&C Green No. 5, D	&C Yellow No. 10, lactose, magnesium stearate, and povidone.	
3.	NOR-QD Watson Labs	28 active pills, one pill daily.	Norethindrone 0.35 mg Tablet; Oral-28
Excipie	nts: D&C Yellow No. 10, FD&C Yellow	No. 6, lactose, magnesium stearate, povidone, and starch.	
4.	LOESTRIN FE 1/20 Warner Chilcott	28 days = 21 days active pills + 7 days inert pills	EE; Norethindrone Acetate 0.02mg; 1 mg Tablet; Oral-28
		C yellow no. 10 aluminum lake, lactose monohydrate, magnesiu , hydrogenated vegetable oil, NF Type I and microcrystalline cel	
5.	LOESTRIN FE 1.5/30 Warner Chilcott	28 days = 21 days active pills + 7 days inert pills	EE; Norethindrone Acetate 0.03mg; 1.5 mg Tablet; Oral-28
		cC red no. 40 aluminum lake HT, lactose monohydrate, magnesi e, hydrogenated vegetable oil, NF Type I and microcrystalline ce	
6.	NORINYL 1+35 21-DAY Watson Labs	21 Days Regimen	EE; Norethindrone 0.035mg; 1 mg Tablet; Oral-21
Excipie	nts: Magnesium stearate, povidone,	maize starch, and lactose.	
7.	NORINYL 1+35 28-DAY Watson Labs	28 days = 21 days active pills + 7 days inert pills	EE; Norethindrone 0.035mg; 1 mg Tablet; Oral-28
		o. 10, lactose, magnesium stearate, povidone, and starch. crocrystalline cellulose, and magnesium stearate.	
8.	OVCON-50, 28-Day Warner Chilcott	28 days = 21 days active pills + 7 days inert pills	EE; Norethindrone 0.05mg; 1 mg Tablet; Oral-28
	nts: dibasic calcium phosphate, D&C sium stearate, povidone, sodium star	Yellow No. 10 (aluminum lake), FD&C Blue No. 1 (aluminum lake) ch glycolate, starch (corn), and talc.	ce), FD&C Yellow No. 6 (aluminum lake), lactoso
9.	LO/OVRAL-28 Wyeth Pharmaceuticals	28 days = 21 days active pills + 7 days inert pills	EE; Norgestrel 0.03mg; 0.3 mg Tablet; Oral-28
Excipie	nts: cellulose, D&C Red 30, lactose,	magnesium stearate, and polacrilin potassium.	
10.	OVCON-35 Warner Chilcott	28 days = 21 days active pills + 7 days inert pills	EE; Norethindrone 0.035mg; 0.4 mg Tablet; Oral-28
sodium	starch glycolate.	um phosphate, FD&C yellow no. 6 aluminum lake, lactose mono ium stearate, and pregelatinized starch.	hydrate, magnesium stearate, povidone and
11.	BREVICON 28-DAY Watson Labs	28 days = 21 days active pills + 7 days inert pills	EE; Norethindrone 0.035mg; 0.5 mg Tablet; Oral-28
		esium stearate, povidone, and starch. icrocrystalline cellulose, and magnesium stearate.	
Inart to			

Table. List of Oral Contraceptive Pills Marketed in United States (Continued)

nized corn starch. 13. LOESTRIN 21 1.5/30 Warner Chilcott Excipients: acacia, compressible sugar, FD& 14. LOESTRIN 21 1/20 Warner Chilcott Excipients: acacia, compressible sugar, D&C 15. ORTHO-NOVUM 1/35-28 Janssen Pharmaceuticals Excipients: FD&C Yellow No. 6, lactose, maginert tablets: D&C Yellow No. 10 Aluminum Lnized corn starch. 16. NORDETTE-28 Duramed Excipients: cellulose, D&C Red 30, FD&C Yellom No. 10 Aluminum Lnized corn starch. 17. ORTHO-NOVUM 7/7/7-28 Janssen Pharmaceuticals Excipients: White tablets: lactose, magnesiu Light peach tablets: FD&C Yellow No. 6, lactose, ninert green tablets: D&C Yellow No. 10 Alumi pregelatinized corn starch. 18. TRI-NORINYL 28-DAY Watson Labs Excipients: Yellow green tablets: D&C Green Blue tablets: FD&C Blue No. 1, lactose, maginert Orange tablets: FD&C Yellow No. 6, lactose, magnert Orange tablets: FD&C Yellow No. 10 Aluminum Lakinert tablet: D & C Yellow No. 2 Aluminum Lakinert tablet: D & C Yellow No. 10 Aluminum Latinized corn starch.	28 days = 21 days active pills + 7 days inert pills I pregelatinized corn starch. ake, FD&C Blue No. 2 Aluminum Lake, lactose, magnesium stear	EE; Norethindrone 0.035 mg; 0.5 mg
Inert tablets: D&C Yellow No. 10 Aluminum L nized corn starch. 13. LOESTRIN 21 1.5/30 Warner Chilcott Excipients: acacia, compressible sugar, FD& 14. LOESTRIN 21 1/20 Warner Chilcott Excipients: acacia, compressible sugar, D&C 15. ORTHO-NOVUM 1/35-28 Janssen Pharmaceuticals Excipients: FD&C Yellow No. 6, lactose, maginert tablets: D&C Yellow No. 10 Aluminum L nized corn starch. 16. NORDETTE-28 Duramed Excipients: cellulose, D&C Red 30, FD&C Yel 17. ORTHO-NOVUM 7/7/7-28 Janssen Pharmaceuticals Excipients: White tablets: lactose, magnesiu Light peach tablets: FD&C Yellow No. 6, lactose, n lnert green tablets: FD&C Yellow No. 10 Alumi pregelatinized corn starch. 18. TRI-NORINYL 28-DAY Watson Labs Excipients: Yellow green tablets: D&C Green Blue tablets: FD&C Blue No. 1, lactose, mag lnert Orange tablets: FD&C Yellow No. 6, lact 19. ORTHO-CYCLEN-28 Janssen Pharmaceuticals Excipients: FD & C Blue No. 2 Aluminum Lak lnert tablet: D & C Yellow No. 10 Aluminum L Linized corn starch.		Tablet; Oral-28
Excipients: acacia, compressible sugar, FD& 14. LOESTRIN 21 1/20 Warner Chilcott Excipients: acacia, compressible sugar, D&C 15. ORTHO-NOVUM 1/35-28 Janssen Pharmaceuticals Excipients: FD&C Yellow No. 6, lactose, maginer tablets: D&C Yellow No. 10 Aluminum Laized corn starch. 16. NORDETTE-28 Duramed Excipients: cellulose, D&C Red 30, FD&C Yellom No. 10 Aluminum Laixen peach tablets: FD&C Yellow No. 6, lactose, magnesiu Light peach tablets: FD&C Yellow No. 6, lactose, nater tablets: FD&C Yellow No. 6, lactose, nater tablets: FD&C Yellow No. 10 Aluminater green tablets: D&C Yellow No. 10 Aluminater green tablets: D&C Yellow No. 10 Aluminater green tablets: FD&C Yellow No. 10 Aluminater green tablets: FD&C Yellow No. 10 Aluminater green tablets: FD&C Yellow No. 6, lactose, magnesiu Light peach tablets: FD&C Yellow No. 10 Aluminater green tablets: FD&C Yellow No. 10 Aluminater tablets: FD&C Blue No. 1, lactose, magner to Grange tablets: FD&C Yellow No. 6, lactose, magner to Grange tablets: FD&C Yellow No. 6, lactose, magner to Grange tablets: FD&C Yellow No. 6, lactose, magner to Grange tablets: FD&C Yellow No. 6, lactose, magner to Grange tablets: FD&C Yellow No. 6, lactose, magner to Grange tablets: FD&C Yellow No. 6, lactose, magner to Grange tablets: FD&C Yellow No. 10 Aluminum Lakuntater tablet: D&C C Yellow No. 2 Aluminum Lakuntater tablet: D&C Yellow No. 10 Aluminum Laku		ate, microcrystalline cellulose, and pregelati
14. LOESTRIN 21 1/20 Warner Chilcott Excipients: acacia, compressible sugar, D&C 15. ORTHO-NOVUM 1/35-28 Janssen Pharmaceuticals Excipients: FD&C Yellow No. 6, lactose, maginert tablets: D&C Yellow No. 10 Aluminum Lnized corn starch. 16. NORDETTE-28 Duramed Excipients: cellulose, D&C Red 30, FD&C Yellor. ORTHO-NOVUM 7/7/7-28 Janssen Pharmaceuticals Excipients: White tablets: lactose, magnesiu Light peach tablets: FD&C Yellow No. 6, lactose, nather tablets: FD&C Yellow No. 10 Alumi pregelatinized corn starch. 18. TRI-NORINYL 28-DAY Watson Labs Excipients: Yellow green tablets: D&C Green Blue tablets: FD&C Blue No. 1, lactose, magnert Orange tablets: FD&C Yellow No. 6, lactose, magnert Orange tablets: FD&C Yellow No. 6, lactose, magnert Orange tablets: FD&C Yellow No. 10 Aluminum Laklance tablets: D&C Blue No. 2 Aluminum Laklance tablet: D&C C Yellow No. 10 Aluminum Laklance t	21 Days regimen	EE; Norethindrone Acetate 0.03 mg; 1.5 mg Tablet; Oral-21
Warner Chilcott Excipients: acacia, compressible sugar, D&C 15. ORTHO-NOVUM 1/35-28 Janssen Pharmaceuticals Excipients: FD&C Yellow No. 6, lactose, maginert tablets: D&C Yellow No. 10 Aluminum Lnized corn starch. 16. NORDETTE-28 Duramed Excipients: cellulose, D&C Red 30, FD&C Yellom No. 10 Aluminum Lnized corn starch. 17. ORTHO-NOVUM 7/7/7-28 Janssen Pharmaceuticals Excipients: White tablets: lactose, magnesiu Light peach tablets: FD&C Yellow No. 6, lactose, numert green tablets: FD&C Yellow No. 10 Aluminum Interest and Interest and Interest Yellow green tablets: D&C Green Blue tablets: FD&C Blue No. 1, lactose, magnert Orange tablets: FD&C Yellow No. 6, lactose, magnert Orange tablets: FD&C Yellow No. 10 Aluminum Laklonert tablet: D & C Yellow No. 2 Aluminum Laklonert tablet: D & C Yellow No. 10 Aluminum Laklonert tablet: D & C Yellow No. 10 Aluminum Laklonert tablet: D & C Yellow No. 10 Aluminum Laklonert tablet: D & C Yellow No. 10 Aluminum Laklonert tablet: D & C Yellow No. 10 Aluminum Laklonert tablet: D & C Yellow No. 10 Aluminum Laklonert tablet: D & C Yellow No. 10 Aluminum Laklonert tablet: D & C Yellow No. 10 Aluminum Laklonert tablet: D & C Yellow No. 10 Aluminum Laklonert tablet: D & C Yellow No. 10 Aluminum Laklonert tablet: D & C Yellow No. 10 Aluminum Laklonert tablet: D & C Yellow No. 10 Aluminum Laklonert tablet: D & C Yellow No. 10 Aluminum Laklonert tablet: D & C Yellow No. 10 Aluminum Laklonert tablet: D & C Yellow No. 10 Aluminum Laklonert tablet: D & C Yellow No. 10 Aluminum Laklonert tablet: D & C Yellow No. 10	C red no. 40 aluminum lake HT, lactose monohydrate, magnesiur	n stearate, and pregelatinized starch.
15. ORTHO-NOVUM 1/35-28 Janssen Pharmaceuticals Excipients: FD&C Yellow No. 6, lactose, maginer tablets: D&C Yellow No. 10 Aluminum Lnized corn starch. 16. NORDETTE-28 Duramed Excipients: cellulose, D&C Red 30, FD&C Yellom No. 10 Aluminum Lnized corn starch. 17. ORTHO-NOVUM 7/7/7-28 Janssen Pharmaceuticals Excipients: White tablets: lactose, magnesiu Light peach tablets: FD&C Yellow No. 6, lactose, nate of tablets: FD&C Yellow No. 10 Aluminate pregelatinized corn starch. 18. TRI-NORINYL 28-DAY Watson Labs Excipients: Yellow green tablets: D&C Green Blue tablets: FD&C Blue No. 1, lactose, magnert Orange tablets: FD&C Yellow No. 6, lactose, magnert Orange tablets: FD&C Yellow No. 10 Aluminum Lak Janssen Pharmaceuticals Excipients: FD & C Blue No. 2 Aluminum Lak Jansten C Yellow No. 10	21 Days regimen	EE; Norethindrone Acetate 0.02mg; 1mg Tablet; Oral-21
Janssen Pharmaceuticals Excipients: FD&C Yellow No. 6, lactose, maginert tablets: D&C Yellow No. 10 Aluminum Linized corn starch. 16. NORDETTE-28 Duramed Excipients: cellulose, D&C Red 30, FD&C Yellow No. 10 Aluminum Linized corn starch. 17. ORTHO-NOVUM 7/7/7-28 Janssen Pharmaceuticals Excipients: White tablets: lactose, magnesiu Light peach tablets: FD&C Yellow No. 6, lactose, not pregelatinized corn starch. 18. TRI-NORINYL 28-DAY Watson Labs Excipients: Yellow green tablets: D&C Green Blue tablets: FD&C Blue No. 1, lactose, magnet Orange tablets: FD&C Yellow No. 6, lactose, magnet Orange tablets: FD&C Yellow No. 6, lactose, magnet Orange tablets: FD&C Yellow No. 6, lactose, magnet Orange tablets: FD&C Yellow No. 1, lactose, magnet Orange tablets: FD&C Yellow No. 6, lactose, magnet Orange tablets: FD&C Yellow No. 1, lactose, magnet Orange tablets: FD&C Yellow No. 6, lactose, magnet Orange tablets: FD&C Yellow No. 1, lactose, magnet Orange tablets: D&C Yellow No.	yellow no. 10 aluminum lake, lactose monohydrate, magnesium	stearate and pregelatinized starch.
Inert tablets: D&C Yellow No. 10 Aluminum L nized corn starch. 16. NORDETTE-28 Duramed Excipients: cellulose, D&C Red 30, FD&C Yel 17. ORTHO-NOVUM 7/7/7-28 Janssen Pharmaceuticals Excipients: White tablets: lactose, magnesiu Light peach tablets: FD&C Yellow No. 6, lactose, n Inert green tablets: FD&C Yellow No. 10 Alumi pregelatinized corn starch. 18. TRI-NORINYL 28-DAY Watson Labs Excipients: Yellow green tablets: D&C Green Blue tablets: FD&C Blue No. 1, lactose, mag Inert Orange tablets: FD&C Yellow No. 6, lact 19. ORTHO-CYCLEN-28 Janssen Pharmaceuticals Excipients: FD & C Blue No. 2 Aluminum Lak Inert tablet: D & C Yellow No. 10 Aluminum L tinized corn starch.	28 days = 21 days active pills + 7 days inert pills	EE; Norethindrone 0.035 mg; 1 mg Tablet; Oral-28
Duramed Excipients: cellulose, D&C Red 30, FD&C Yel 17. ORTHO-NOVUM 7/7/7-28 Janssen Pharmaceuticals Excipients: White tablets: lactose, magnesiu Light peach tablets: FD&C Yellow No. 6, lactose, nelloert green tablets: FD&C Yellow No. 10 Alumi pregelatinized corn starch. 18. TRI-NORINYL 28-DAY Watson Labs Excipients: Yellow green tablets: D&C Green Blue tablets: FD&C Blue No. 1, lactose, mag Inert Orange tablets: FD&C Yellow No. 6, lact 19. ORTHO-CYCLEN-28 Janssen Pharmaceuticals Excipients: FD & C Blue No. 2 Aluminum Lak Inert tablet: D & C Yellow No. 10 Aluminum L tinized corn starch.	nesium stearate and pregelatinized corn starch. ake, FD&C Blue No. 2 Aluminum Lake, lactose, magnesium stear	ate, microcrystalline cellulose , and pregelat
17. ORTHO-NOVUM 7/7/7-28 Janssen Pharmaceuticals Excipients: White tablets: lactose, magnesiu Light peach tablets: FD&C Yellow No. 6, lactore, not tablets: FD&C Yellow No. 10 Alumi pregent tablets: D&C Yellow No. 10 Alumi pregelatinized corn starch. 18. TRI-NORINYL 28-DAY Watson Labs Excipients: Yellow green tablets: D&C Green Blue tablets: FD&C Blue No. 1, lactose, mag Inert Orange tablets: FD&C Yellow No. 6, lact 19. ORTHO-CYCLEN-28 Janssen Pharmaceuticals Excipients: FD & C Blue No. 2 Aluminum Lak Inert tablet: D & C Yellow No. 10 Aluminum L tinized corn starch.	28 days = 21 days active pills + 7 days inert pills	EE; Levonorgestrel 0.03 mg; 0.15 mg Tablet; Oral-28
Janssen Pharmaceuticals Excipients: White tablets: lactose, magnesiu Light peach tablets: FD&C Yellow No. 6, lactose, n Peach tablets: FD&C Yellow No. 6, lactose, n Inert green tablets: D&C Yellow No. 10 Alumi pregelatinized corn starch. 18. TRI-NORINYL 28-DAY Watson Labs Excipients: Yellow green tablets: D&C Green Blue tablets: FD&C Blue No. 1, lactose, mag Inert Orange tablets: FD&C Yellow No. 6, lact 19. ORTHO-CYCLEN-28 Janssen Pharmaceuticals Excipients: FD & C Blue No. 2 Aluminum Lak Inert tablet: D & C Yellow No. 10 Aluminum L Itinized corn starch.	low 6, lactose, magnesium stearate, and polacrilin potassium	
Light peach tablets: FD&C Yellow No. 6, lactore Peach tablets: FD&C Yellow No. 6, lactose, not not green tablets: D&C Yellow No. 10 Aluming Pregelatinized corn starch. 18. TRI-NORINYL 28-DAY Watson Labs Excipients: Yellow green tablets: D&C Green Blue tablets: FD&C Blue No. 1, lactose, magnert Orange tablets: FD&C Yellow No. 6, lactore Inc. ORTHO-CYCLEN-28 Janssen Pharmaceuticals Excipients: FD & C Blue No. 2 Aluminum Lak Inert tablet: D & C Yellow No. 10 Aluminum L tinized corn starch.	28 days = 21 (7+7+7) days active pills + 7 days inert pills	EE; Norethindrone 0.035 mg,0.035 mg,0.035 mg; 0.5 mg,0.75mg,1 mg Tablet; Oral-28
Watson Labs Excipients: Yellow green tablets: D&C Green Blue tablets: FD&C Blue No. 1, lactose, mag Inert Orange tablets: FD&C Yellow No. 6, lact 19. ORTHO-CYCLEN-28 Janssen Pharmaceuticals Excipients: FD & C Blue No. 2 Aluminum Lak Inert tablet: D & C Yellow No. 10 Aluminum L tinized corn starch.	m stearate and pregelatinized corn starch. ose, magnesium stearate and pregelatinized corn starch. nagnesium stearate and pregelatinized corn starch. num Lake, FD&C Blue No. 2 Aluminum Lake, lactose, magnesium	ı stearate, microcrystalline cellulose, and
Blue tablets: FD&C Blue No. 1, lactose, mag Inert Orange tablets: FD&C Yellow No. 6, lact 19. ORTHO-CYCLEN-28 Janssen Pharmaceuticals Excipients: FD & C Blue No. 2 Aluminum Lak Inert tablet: D & C Yellow No. 10 Aluminum L tinized corn starch.	28 days = 21 (7+9+5) days active pills + 7 days inert pills	EE; Norethindrone 0.035 mg,0.035 mg,0.035 mg; 0.5 mg,1mg,0.5 mg Tablet; Oral-28
Janssen Pharmaceuticals Excipients: FD & C Blue No. 2 Aluminum Lak Inert tablet: D & C Yellow No. 10 Aluminum L tinized corn starch.	No. 5, D&C Yellow No. 10, lactose, magnesium stearate, povidon nesium stearate, povidone, and starch. ose, microcrystalline cellulose, and magnesium stearate.	e, and starch.
Inert tablet: D & C Yellow No. 10 Aluminum L linized corn starch.	28 days = 21 days active pills + 7 days inert pills	EE; Norgestimate 0.035mg; 0.25 mg & 0.035 mg; 0.25 mg Tablet; Oral-28
00 Decedes	e, lactose, magnesium stearate, and pregelatinized corn starch. ake, FD & C Blue No. 2 Aluminum Lake, lactose, magnesium stea	arate, microcrystalline cellulose , and pregel
20. Desogen Organon USA Inc	28 days = 21 days active pills + 7 days inert pills	Desogestrel; EE 0.15 mg; 0.03 mg Tablet; Oral-28
dioxide, and talc.	stearic acid, colloidal silicon dioxide, lactose, hydroxypropyl me gnesium stearate, FD&C Blue No. 2 aluminum lake, ferric oxide, h	

■ Alam · Ali · Al-Jenoobi · Al-mohizea

Table. List of Oral Contraceptive Pills Marketed in United States (Continued)

No.	Brand/ Company/ Approval Year	Regimen	Product Strength
21.	ORTHO-CEPT Janssen Pharmaceuticals	28 days = 21 days active pills + 7 days inert pills	Desogestrel; EE 0.15 mg; 0.03 mg Tablet; Oral-28
dioxide nert g	e, and vitamin E	ch, ferric oxide, lactose, hypromellose, lactose, polyethylene gl Lake, ferric oxide, hypromellose, lactose, magnesium stearate	
22.	ORTHO TRI-CYCLEN Janssen Pharmaceuticals	28 days = 21 (7+7+7) days active pills + 7 days inert pills	EE; Norgestimate 0.035 mg,0.035 mg,0.035 mg; 0.18 mg,0.215 mg,0.25 mg Tablet; Oral-28
ight b Blue ta nert g	lue tablets: FD & C Blue No. 2 Aluminun ıblets: FD & C Blue No. 2 Aluminum Lako	se, magnesium stearate, and pregelatinized corn starch. n Lake, lactose, magnesium stearate, and pregelatinized corn s e, lactose, magnesium stearate, and pregelatinized corn starch num Lake, FD & C Blue No. 2 Aluminum Lake, lactose, magnesi	
23.	ESTROSTEP Fe Warner Chilcott	28 days = 21 (7+7+7) days active pills + 7 days inert pills	EE; Norethindrone Acetate 0.02 mg,0.03 mg,0.035 mg; 1 mg,1 mg,1 mg Tablet; Oral-28
nert ta Excipie		rstalline cellulose; and starch. Is fumarate; magnesium stearate; povidone; sodium starch glyc nesium stearate, hydroxypropyl methylcellulose, titanium dioxid	
24.	Plan B Teva Womens' Health	Emergency Contraceptive	Levonorgestrel 0.75 mg Tablet; Oral
Excipie	ents: colloidal silicon dioxide, potato sta	rch, gelatin, magnesium stearate, talc, corn starch, and lactose	e monohydrate.
25.	Cyclessa Organon USA Inc	28 days = 21 (7+7+7) days active pills + 7 days inert pills	Desogestrel; EE 0.1 mg,0.125 mg,0.15 mg; 0.025 mg,0.025 mg,0.025 mg Tablet; Oral-28
yellow Inert ta	ferric oxide (in light yellow and orange to	earic acid, lactose monohydrate, hydroxypropyl methylcellulose ablets), and red ferric oxide (in orange and red tablets). n, magnesium stearate, hydroxypropyl methylcellulose, polyethy	
26.	YASMIN Bayer Healthcare	28 days = 21 days active pills + 7 days inert pills	Drospirenone; EE 3 mg; 0.03 mg Tablet; Oral-28
0000	NF, titanium dioxide USP, talc USP, and f	ch NF, pregelatinized starch NF, povidone 25000 NF, magnesiur erric oxide pigment, yellow NF. arch NF, povidone 25000 NF, magnesium stearate NF, hyprome	
27.	ORTHO TRI-CYCLEN Lo Janssen Pharmaceuticals	28 days = 21 (7+7+7) days active pills + 7 days inert pills	EE; Norgestimate 0.025 mg,0.025 mg,0.025 mg; 0.18 mg,0.215 mg,0.25 mg

Excipients: White tablets: Lactose, magnesium stearate, croscarmellose sodium, microcrystalline cellulose, carnauba wax, hydroxypropylmethylcellulose, polyethylene glycol, titanium dioxide, and purified water.

Light blue tablets: FD & C Blue No. 2 Aluminum Lake, lactose, magnesium stearate, croscarmellose sodium, microcrystalline cellulose, carnauba wax, hydroxypropylmethylcellulose, polyethylene glycol, titanium dioxide, and purified water.

Blue tablets: FD & C Blue No. 2 Aluminum Lake, lactose, magnesium stearate, croscarmellose sodium, microcrystalline cellulose, polysorbate 80, carnauba wax, hydroxypropylmethylcellulose, polyethylene glycol titanium dioxide, and purified water.

Inert green tablets: FD & C Blue No. 1 Aluminum Lake, lactose, magnesium stearate, pregelatinized starch, ferric oxide, hydroxypropylmethylcellulose, polyethylene glycol, titanium dioxide, talc, and purified water.

(Continued)

Tablet: Oral-28

Table. List of Oral Contraceptive Pills Marketed in United States (Continued)

S. No.	Brand/ Company/ Approval Year	Regimen	Product Strength
28.	SEASONALE Duramed Pharmaceuticals	91 days = 84 days active pills + 7 days inert pills	EE; Levonorgestrel 0.03 mg; 0.15 mg Tablet; Oral
NF, ma	gnesium stearate NF, polysorbate 80 NI	no. 1, FD&C red no. 40, hydroxypropyl methylcellulose USP, mio F, and titanium dioxide USP. opyl methylcellulose USP, microcrystalline cellulose NF, and ma	
29.	ORTHO TRI-CYCLEN-21 Ortho McNeil Pharmaceutical	28 days = 21 (7+7+7) days active pills + 7 pill free days	EE; Norgestimate 0.035 mg,0.035mg,0.035 mg; 0.18 mg,0.215 mg,0.25 mg Tablet; Oral-21
Light B		stearate, and pregelatinized starch. n Lake, lactose, magnesium stearate, and pregelatinized starc e, lactose, magnesium stearate, and pregelatinized starch.	h.
30.	ORTHO TRI-CYCLEN-28 Ortho McNeil Pharmaceutical	28 days = 21 (7+7+7) days active pills + 7 days inert pills	EE; Norgestimate 0.035 mg,0.035 mg,0.035 mg; 0.18 mg,0.215 mg,0.25 mg Tablet; Oral-28
Light bl Blue ta Inert gr	blets: FD & C Blue No. 2 Aluminum Lak	stearate, and pregelatinized starch. n Lake, lactose, magnesium stearate, and pregelatinized starc e, lactose, magnesium stearate, and pregelatinized starch. num Lake, FD & C Blue No. 2 Aluminum Lake, lactose, magnes	
31.	SEASONIQUE Teva Womens' Health	91 days = 84 days active pills + 7 days EE pills	EE; Levonorgestrel 0.03 mg,0.01mg; 0.15 mg,n/a Tablet; Oral
low alu Inert Ta	minum lake, hypromellose, lactose mor ablets: anhydrous lactose, D&C yellow n	s lactose, D&C yellow no. 10 aluminum lake, FD&C blue no. 1 anohydrate, magnesium stearate, microcrystalline cellulose, tita o. 10 aluminum lake, FD&C yellow no. 6/Sunset yellow alumin n, polyethylene glycol, polysorbate 80 and titanium dioxide.	nium dioxide and triacetin.
32.	YAZ Bayer Healthcare	28 days = 24 days active pills + 4 days inert pills	Drospirenone; EE 3 mg; 0.02 mg Tablet; Oral
ment, r	red NF.	corn starch NF, magnesium stearate NF, hypromellose USP, tal arch NF, povidone 25000 USP, magnesium stearate NF, hypron	, , ,
33.	LOESTRIN 24 FE Warner Chilcott	28 days = 24 days active pills + 4 days inert pills	EE; Norethindrone Acetate 0.02 mg; 1 mg Tablet; Oral
		te, starch, confectioner's sugar, and talc. e cellulose, magnesium stearate, povidone, sodium starch glyc	colate, and compressible sugar.
34.	LYBREL Wyeth Pharmaceuticals Inc	28 days = 28 active pills, one pill daily	EE; Levonorgestrel 0.02 mg; 0.09 mg Tablet; Oral
	ents: Microcrystalline cellulose, lactose on oxide, polyethylene glycol 1450, moi	monohydrate, magnesium stearate, polacrilin potassium, hypr ntanic ester wax.	omellose, titanium dioxide, polyethylene glycol
35.	LOSEASONIQUE Teva Womens' Health	91 days = 84 days active pills + 7 days EE pills	EE; Levonorgestrel 0.02 mg,0.01 mg; 0.1 mg,N/A Tablet; Oral

Excipients: FD&C Yellow # 6 (Sunset Yellow) aluminum lake, hypromellose, lactose, magnesium stearate, microcrystalline cellulose, corn starch, titanium dioxide and triacetin.

Inert tablets: anhydrous lactose, FD&C Yellow # 10 aluminum lake, FD&C Yellow # 6 (Sunset Yellow) aluminum lake, hypromellose, magnesium stearate, microcrystalline cellulose, polacrilin potassium, polyethylene glycol, polysorbate 80, and titanium dioxide.

(Continued)

Table. List of Oral Contraceptive Pills Marketed in United States (Continued)

S. No.	Brand/ Company/ Approval Year	Regimen	Product Strength		
36.	PLAN B ONE-STEP Duramed Pharmaceuticals	Single dose Emergency contraceptive	Levonorgestrel 1.5 mg Tablet, Oral		
Excipie	nts: colloidal silicon dioxide, corn starch	, lactose monohydrate, magnesium stearate, potato starch, and	talc.		
37.	NATAZIA Bayer Healthcare	28 days = 26 (2+5+17+2) days active pills + 2 days inert pills	Dienogest; Estradiol Valerate N/A,2 mg,3 mg,N/A,N/A; 3 mg,2 mg,2 mg,1 mg,N/A Tablet; Oral-28		
	nts: lactose monohydrate, maize starch, n dioxide, and ferric oxide pigment, yello	maize starch pre-gelatinized, povidone 25, magnesium stearate w, or ferric oxide pigment, red.	, hypromellose, macrogol 6000, talc,		
38.	BEYAZ Bayer Healthcare	28 days = 24 days active pills + 2 days inert pills	Drospirenone; EE; Levomefolate Calcium 3 mg,N/A; 0.02 mg,N/A; 0.451 mg,0.451 mg Tablet; Oral		
dioxide, Inert ta	Excipients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose, magnesium stearate, hypromellose, titanium dioxide, talc, polyethylene glycol, ferric oxide pigment, red. Inert tablets: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, hydroxypropyl cellulose, magnesium stearate, hypromellose, titanium dioxide, talc, polyethylene glycol, ferric oxide pigment, red, ferric oxide pigment, yellow.				
39.	LO LOESTRIN FE Warner Chilcott Co	28 days = 26(24+2) days active pills + 2 days inert pills	EE; norethindrone acetate 0.01 mg, 1 mg, Tablet; oral Ethinyl Estradiol: 10 mcg Tablet; oral Ferrous fumarate: 75 mg tablet; oral		
vitamin White t	E and lactose monohydrate. tablets: Mannitol, microcrystalline cellul own tablets: ferrous fumarate, mannitol,	ine cellulose, FD&C Blue No. 1 Aluminum Lake, sodium starch gose, sodium starch glycolate, magnesium stearate, povidone, vit povidone, microcrystalline cellulose, sodium starch glycolate, m	amin E and lactose monohydrate.		
40.	SAFYRAL Bayer Healthcare	28 days = 21 days active pills + 7 days inert pills	Drospirenone; EE; Levomefolate Calcium 3 mg,N/A; 0.03 mg,N/A; 0.451 mg,0.451 mg Tablet; Oral		
mellose Inert ta	e USP, titanium dioxide USP, talc USP, po blets: lactose monohydrate NF, microcry	alline cellulose NF, croscarmellose sodium NF, hydroxypropyl cel lyethylene glycol NF, ferric oxide pigment, yellow NF, and ferric o stalline cellulose NF, croscarmellose sodium NF, hydroxypropyl c lyethylene glycol NF and ferric oxide pigment, yellow NF, and ferr	xide pigment, red NF. cellulose NF, magnesium stearate NF, hypro-		
41.	NORETHINDRONE AND ETHINYL ES- Tradiol and Ferrous Fumarate Watson Labs Inc	28 days = 24 days active pills + 4 days inert pills	EE; Norethindrone 0.025mg; 0.8mg Tablet, Chewable; Oral		
stearate	e, mannitol, microcrystalline cellulose, p	D&C Blue No. 1 aluminum lake, FD&C Yellow No. 6 aluminum lal ovidone, sodium starch glycolate, spearmint flavor, sucralose an arate, mannitol, microcrystalline cellulose, povidone, sodium sta	d vitamin E.		

(ulipristal acetate 30 mg; Lab HRA Pharma) provides a more flexible emergency contraceptive regimen; the regimen recommends 1 oral tablet as soon as possible within 120 hours (5 days) after unprotected intercourse or a known or suspected contraceptive failure. Emergency contraceptives are not abortifacient (ie, they do not terminate an existing pregnancy) and do not prevent pregnancy from acts of unprotected intercourse later in

that menstrual cycle. 40,41 The emergency contraceptive kit

(Preven) consists of 4 emergency contraceptive pills and a pregnancy test. The first dose of Preven should be taken as soon as possible; initially, 2 pills should be taken within 72 hours of unprotected intercourse, followed by the second dose of 2 pills 12 hours later.

CONTRACEPTIVE REGIMENS16,39

Most contraceptive regimens recommend 1 pill every day at an interval not exceeding 24 hours. The pill should

be taken as recommended at the same time each day, because the risk of pregnancy increases with each missed pill.8,42 In medical conditions like vomiting or diarrhea, an extra pill can be taken from a spare pack or a backup contraceptive plan should be considered to avoid unwanted pregnancy.43

Combined oral contraceptive pill regimens can be started on either the first Sunday after the onset of menstruation (Sunday start) or on day 1 of menstruation (day 1 start). If menstruation begins on Sunday, the first pill should be taken on that day. During the first cycle, it is recommended that Sunday starters use a nonhormonal backup contraceptive plan for the first 7 days. 44-46 Day 1 starters do not require any backup contraceptive plan for first 7 days because the first 7 days of menstruation are considered to be a safe period. 44,47 If a day 1 starter begins the regimen later than day 1 of menstruation, then a nonhormonal contraceptive backup plan is recommended for first 7 days.⁴² The nonhormonal contraceptive backup plan includes the use of birth control methods such condoms, diaphragms, and spermicidal gels.

Three contraceptive dosing regimens of 21, 28, and 91 days have been introduced. The 21-day dosing regimen provides 1 contraceptive pill daily for 21 days, followed by 7 pill-free days (see Table). The 28-day regimen was introduced to improve consumer compliance compared with the 21-day regimen. With the 28-day regimen, there is no need to count days between cycles because there are no off-tablet days. There are four 28-day regimens: 21 active + 7 inert pills, 24 active + 4 inert pills, 26 active + 2 inert pills, and 28 active pills. With the 21+7 regimen, 1 active pill is taken daily for 21 days, followed by 1 inert (hormone-free) pill daily for next 7 days (see Table). The inert tablets are provided to facilitate correct administration; consumers don't need to count days between cycles because there is no tablet-free day in whole cycle. With the 24+4 regimen, 1 active pill is taken daily for 24 days, followed by 1 inert (hormone-free) pill daily for next 4 days. Another 28-day regimen (Natazia) provides 26(2 + 5 + 17 + 2) active pills and 2 inert pills. Lo Loestrin Fe provides 26 active pills (24 with norethindrone acetate and ethinyl estradiol, 2 with ethinyl estradiol) and 2 inert tablets. The 28-day regimens of Lybrel, Ortho-Micronor, and Nor-QD are different from other regimens because all 28 pills are active (norethindrone); 1 pill is taken daily for 28 days. The extended-cycle regimen of 91 days recommends 1 active pill daily for 84 days, followed by 1 inert or estrogen pill daily for next 7 days.

GUIDELINES TO MANAGE MISSED PILLS

Missed pills enhance the chance of contraceptive failure. Missed pills are managed on the basis of 4 criteria: (1) how many pills were missed, (2) at what stage pills were missed, (3) the progestin content of the missed pills, and (4) the dose regimen. In a 28-day (21+7) regimen, if 1 active pill is missed in the first, second, or third week of the cycle, take it as soon as remembered and take the next pill at the regular time (1+1 pill in a day). No backup contraceptive plan is required. If 2 active pills are missed in a row in the first or second week, take 2 pills on the day the pills are remembered and 2 pills the next day; thereafter continue the regular regimen. A contraceptive backup plan (nonhormonal birth control method such as condoms or spermicide) is recommended for next 7 days after restart of the missed pills if intercourse is planned for these days. If 2 active pills are missed in a row in the third week or if 3 or more active pills are missed in a row at any time, a day 1 starter should discard the remaining pills and start with a new pill pack that same day, and a Sunday starter should keep taking 1 pill every day until Sunday; on Sunday, she should discard the rest of the pills and start with a new pill pack that same day. A contraceptive backup plan (nonhormonal birth control method such as condoms or spermicide) is recommended for the next 7 days after restart of a new pill pack if intercourse is planned for these 7 days. 42 If any of hormone-free pills are missed in the fourth week, throw away the missed pills and keep taking 1 pill each day until the pack is empty. No backup contraceptive plan is recommended. After completion of the cycle, start a new pack on the same day.

With extended regimens like 28 (24+4) days, 28 (26+2) days, or 91 (84+7) days, if 1 active pill is missed in the first, second, or third week or if 2 pills are missed in a row in the first or second week, management is similar to that with the 21+7 day regimen. With a 28-day (24+4 or 26+2) regimen, if 2 active pills are missed in a row in the third or fourth week, or if 3 or more active pills are missed in a row at any time during the cycle, a day 1 starter should discard the remaining pills and start with a new pill pack that same day, and a Sunday starter should keep taking 1 pill every day until Sunday; on Sunday she should discard the rest of the pills and start with a new pill pack that same day. For both day 1 and Sunday starters, a backup plan is recommended. If 3 or more active tablets are missed in a row with the extended-cycle regimen, do not take the missed pills and keep taking 1 pill daily as directed until you finish the pack. A nonhormonal contraceptive backup plan is recommended for the first 7 days after restart of the normal schedule if intercourse is desired for these 7 days. The extended-cycle regimen of Seasonique and LoSeasonique consists of 91 (84+7) active pills. The last 7 pills of these regimens contain ethinyl estradiol as the active substance. If any of these last 7 yellow pills is missed, discard the missed pill and continue with the regular regimen until the pack is finished. No backup plan is recommended.

Natazia and Lybrel have different guidelines to manage missed pills. Start the Natazia regimen on the first day of your menstrual bleeding by taking the first dark-yellow pill. A nonhormonal contraceptive backup plan is recommended for the first 9 days. If 1 Natazia pill is missed for more than 12 hours on days 1 through 17, take the missed pill immediately, then take your next pill at usual time (1+1) and follow the regular regimen. A nonhormonal contraceptive backup plan is recommended for next 9 days. If 1 pill is missed for more than 12 hours on days 18 through 24, discard the remaining pills, and take the day 1 pill from a new pack and continue with the regular regimen. A nonhormonal contraceptive backup plan is recommended for next 9 days. If 1 pill is missed for more than 12 hours on days 25 through 28, take the missed pill immediately and next pill of the day at the usual time (1+1), and then continue the regular regimen. No backup contraception is needed. If 2 pills are missed in a row on days 1 through 17, do not take the missed pill; instead, take the pill of the day when you notice that you missed the pill and continue the regular regimen. Use backup contraception for next 9 days. If pills for days 17 and 18 are missed, follow the instructions for days 17 through 25 instead. If 2 pills are missed in a row on days 17 through 25, discard all the remaining pills, take the day 3 pill from a new pack, and continue the regular regimen. Use backup contraception for next 9 days. If pills for days 25 and 26 are missed, then follow the instructions for days 25 through 28 instead. If 2 pills are missed in a row on days 25 through 28, discard all the remaining pills, start with a new pack on the same day or on the usual day a new pack is started, and continue with the regular regimen. No backup plan is required.

If 1 Lybrel is missed, take the missed pill as soon as remembered and next pill at regular time (1+1 pill); a non-hormonal contraceptive backup plan is recommended for 7 days. If 2 Lybrel tablets are missed in a row and remembered on the day of second missed pill, take 2 pills on the day you remember and then follow the regular regimen; a nonhormonal contraceptive backup plan is recommended. If 2 Lybrel tablets are missed in a row and remembered on the day after second pill is missed, take 2 pills on the day remembered and 2 pills the next day, followed

by the regular regimen; a 7-day nonhormonal contraceptive backup plan is recommended. If 3 or more pills are missed in a row, do not take the missed pills, contact your healthcare provider for advice, and keep taking 1 pill every day; a 7-day nonhormonal contraceptive backup plan is recommended.

The regimens of Ortho-Micronor and NOR-QD are different from other conventional regimens because these products are progestin-only contraceptives and consist of 28 active tablets. If a regimen is started on a day other than first menstrual day, a nonhormonal contraceptive backup plan is recommended for next 48 hours. If a pill is taken more than 3 hours late or if 1 or more pills are missed, take the missed pills as soon as you remember and then follow the regular regimen at the right time. A nonhormonal contraceptive backup plan is recommended for next 48 hours.

FUTURE PERSPECTIVES

Over the years, several progestin and estrogen combinations have been approved for birth control. Numerous dose regimens and cyclic regimens have been provided to improve the safety and tolerability of contraceptive pills. Furthermore, attempts have been made to simplify the dosing schedule by introducing inert pills, marking days over pills pack (wallet card), differentiating pills by their color and shape, and using dispensers like a dial pack or click case. Still, there is room to improve patient compliance by developing a simple and flexible dosing schedule. Also needed are some other new combinations of estrogen and progestin that are free from thromboembolic adverse effects and safe for smokers and others. The simple, new, and safer dosing regimen should be included in the list of extended-cycle regimens, which are free from intermittent unscheduled bleeding. More user-friendly products like chewable pills or orally dispersible pills may also improve compliance because these products can be consumed without water.

CONCLUSION

Combined oral contraceptive pills are considered to be an effective birth control method when used regularly on a prescribed schedule, with missed pills being managed according to guidelines. The Sunday starters are advised to use a nonhormonal contraceptive backup plan for first 7 days if intercourse is desired. Nonhormonal contraceptive backup plans are also advised for 7 days when 2 or more pills are missed in a row and intercourse is desired in the 7 days after resuming the normal regimen. Introduction of 28-day (21+7, 24+4,

or 26+2) regimens and the use of a pill dispenser (dial pack, click case) improve users' compliance. Biphasic, triphasic, or quadriphasic dose regimens have not proven to be more efficacious than a monophasic regimen. Emergency contraceptive pills are recommended only the case of unprotected intercourse or when the regular contraceptive method fails. Emergency contraceptives are not recommended for routine use and are ineffective or less effective when used before or delayed more than 120 hours after sex.

Acknowledgments

The authors wish to thank Research Centre, College of Pharmacy, King Saud University, Riyadh for funding this research project.

Author Affiliations: From College of Pharmacy, King Saud University, Saudi Arabia (MAA, FIA, AMA); Research Centre, College of Pharmacy, King Saud University, Saudi Arabia (RA).

Funding Source: Research Centre, College of Pharmacy, King Saud University, Riyadh funded this project.

Author Disclosures: Concept and design (MAA, FIA-J); acquisition of data (MAA, RA); drafting of the manuscript (MAA, RA, AMA-m, FIA-J); critical revision of the manuscript for important intellectual content (MAA, RA); obtaining funding (AMA-m, FIA-J); and supervision (MAA, FIA-J).

Address correspondence to: Mohd. Aftab Alam, PhD, College of Pharmacy, King Saud University, PO Box 2457, Riyadh 11451, Saudi Arabia. Email: afealam@rediffmail.com.

REFERENCES

- 1. Himmerick KA. Enhancing contraception: a comprehensive review. JAAPA. 2005;18(7):26-33.
- 2. Contraceptive Updates Reference Manual for Doctors. October 2005. http://india. unfpa.org/drive/Referencemanualfordoctors.pdf.
- 3. Sengupta J. Accessing modern contraceptive technologies in India. Indian J Physiol Pharmacol. 2006;50(4):327-340.
- 4. US Food and Drug Administration. Birth Control Guide. http://www.fda.gov/ downloads/ForConsumers/ByAudience/ForWomen/FreePublications/UCM356451.
- 5. Rosenberg MJ, Burnhill MS, Waugh MS, Grimes DA, Hillard PJ. Compliance and oral contraceptives: a review. Contraception. 1995;52(3):137-141.
- 6. Rosenberg M, Waugh MS. Causes and consequences of oral contraceptive noncompliance. Am J Obstet Gynecol. 1999;180 (2, pt 2):276-279.
- 7. Al-Shaikh GK, Mayet AY, Alshaikh MK, Hamad AF, Mahmoud MA, Aljadhey HS. Knowledge on adherence and safety of the oral contraceptive pill in Saudi women. Saudi Med J. 2012;33(6):665-670.
- 8. Barjot P, Graesslin O, Cohen D, Vaillant P, Clerson P, Hoffet M. Pregnancies occurring during oral contraception: lessons from the GRECO study [in French]. Gynecol Obstet Fertil. 2006;34(2):120-126.
- 9. Fontenot HB, Harris AL. The latest advances in hormonal contraception. J Obstet Gynecol Neonatal Nurs. 2008;37(3):369-374.
- 10. Lete I, Doval JL, Pérez-Campos E, et al. Factors affecting women's selection of a combined hormonal contraceptive method: the TEAM-06 Spanish cross-sectional study. Contraception. 2007;76(2):77-83.
- 11. Ozalp S, Yalcin OT, H, Hassa H, Erbay B, Dalan N. Factors affecting the selection of a reversible or an irreversible contraceptive method in a developing country. Eur J Contracept Reprod Health Care. 2000;5(2):147-151.
- 12. Beckman LJ, Harvey SM. Factors affecting the consistent use of barrier methods of contraception. Obstet Gynecol. 1996;88(3 suppl):65s-71s.
- 13. Ahmed T. Contraceptive methods choice in Pakistan: determined or predetermined. Pak Dev Rev. 1994;33(4, pt 2):773-797.
- 14. Grady WR, Billy JO, Klepinger DH. Contraceptive method switching in the United States. Perspect Sex Reprod Health. 2002;34(3):135-145.

- 15. Mishell DR Jr, Darney PD, Burkman RT, Sulak PJ. Practice guidelines for OC selection: update. Dialogues Contracept. 1997;5(4):7-20.
- 16. US Food and Drug Administration. Home page. http://www.fda.gov. Updated July 25, 2014. Accessed August 29, 2012.
- 17. Reid RL. Oral contraceptives and venous thromboembolism: pill scares and public health. J. Obstet Gynaecol Can. 2011;33(11):1150-1155.
- 18. Krishnan S, Kiley J. The lowest-dose, extended-cycle combined oral contraceptive pill with continuous ethinyl estradiol in the United States: a review of the literature on ethinyl estradiol 20 μg/levonorgestrel 100 μg + ethinyl estradiol 10 μg. Int J Womens Health. 2010;2:235-239.
- 19. Kiley J. Hammond C. Combined oral contraceptives: a comprehensive review. Clin Obstet Gynecol. 2007;50(4):868-877.
- 20. Sondheimer SJ. Oral contraceptives: mechanism of action, dosing, safety, and efficacy. Cutis. 2008;81(1suppl): 19-22.
- 21. Van Vliet HA, Grimes DA, Helmerhorst FM, Schulz KF. Biphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev. 2006; (3):CD002032.
- 22. Van Vliet HA, Grimes DA, Lopez LM, Schulz KF, Helmerhorst FM. Triphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev. 2006;(3):CD003553.
- 23. Van Vliet HA, Grimes DA, Helmerhorst FM, Schulz KF. Biphasic versus triphasic oral contraceptives for contraception. Cochrane Database Syst Rev. 2006;(3): CD003283.
- 24. Holzgreve W, Pietrzik K, Koletzko B, Eckmann-Scholz C. Adding folate to the contraceptive pill: a new concept for the prevention of neural tube defects. J Matern Fetal Neonatal Med. 2012;25(9):1529-1536.
- 25. Fruzzetti F. Beyaz®: an oral contraceptive fortified with folate. Womens Health (Lond Engl). 2012;8(1):13-19.
- 26. Rapkin RB, Creinin MD. The combined oral contraceptive pill containing drospirenone and ethinyl estradiol plus levomefolate calcium. Expert Opin Pharmacother. 2011;12(15):2403-2410.
- 27. Wright KP. Johnson JV. Evaluation of extended and continuous use oral contraceptives. Ther Clin Risk Manag. 2008;4(5):905-911.
- 28. Nelson A. New low-dose, extended-cycle pills with levonorgestrel and ethinyl estradiol: an evolutionary step in birth control. Int J Womens Health. 2010;
- 29. Allen RH, Goldberg AB. Emergency contraception: a clinical review. Clin Obstet Gynecol. 2007;50(4):927-936.
- 30. Trussell J, Raymond EG, Cleland K. Emergency Contraception: A Last Chance to Prevent Unintended Pregnancy. http://ec.princeton.edu/questions/ec-review.pdf. Published July 2014. Accessed July 25, 2014.
- 31. Blaney CL. Contraception after unprotected sex. Netw Res Triangle Park N C. 1994;15(2):4-8.
- 32. Leung VW, Levine M, Soon JA. Mechanisms of action of hormonal emergency contraceptives. Pharmacotherapy. 2010;30(2):158-168.
- 33. Emergency contraception: it can change our world: an interview with James Trussell. Fam Life Matters. 1999;36:3-5.
- 34. Faúndes, Brache V, Alvarez F. Emergency contraception—clinical and ethical aspects. Int J Gynaecol Obstet. 2003;82(3):297-305.
- 35. van Santen MR, Haspels AA. Postcoital interception with steroids. Wien Med Wochenschr. 1987;137(18-19):465-470.
- 36. Bastianelli C, Farris M, Benagiano G. Emergency contraception: a review. Eur J Contracept Reprod Health Care. 2008;13(1):9-16.
- 37. US Food and Drug Administration. Prescription drug products; certain combined oral contraceptives for use as postcoital emergency contraception. Federal Register. 1997;62(27):8609-8612. http://www.hhs.gov/opa/pdfs/opa-97-02-attachment.pdf. Accessed August 30, 2012.
- 38. Yuzpe AA, Thurlow HJ, Ramzy I, Leyshon JI. Post coital contraception—a pilot study. J Reprod Med. 1974;13(2):53-58.
- 39. Creinin MD. A reassessment of efficacy of the Yuzpe regimen of emergency contraception. Hum Reprod. 1997;12(3):496-498.
- 40. Noe G, Croxatto HB, Salvatierra AM, et al. Contraceptive efficacy of emergency contraception with levonorgestrel given before or after ovulation. Contraception. 2011;84(5):486-492.

■ Alam · Ali · Al-Jenoobi · Al-mohizea

- 41. Durand M, Larrea F, Schiavon R. Mechanism of action of emergency contraception [in Spanish]. *Salud Publica Mex.* 2009;51(3):255-261.
- 42. Guilbert E, Black A, Dunn S, et al. Missed hormonal contraceptives: new recommendations. *J Obstet Gynaecol Can.* 2008;30(11):1050-1062, 1063-1077. English, French.
- 43. Kovacs GT, Murtagh J. Survey of general practitioner instructions to oral contraceptive users. *Aust Fam Physician*. 1994;23(5):915-918.
- 44. Standardized instructions urged for OCs. FDA Med Bull. 1992;22(2):6-7.
- 45. Williams-Deane M, Potter LS. Current oral contraceptive use instructions: an analysis of patient package inserts. *Fam Plann Perspect.* 1992;24(3):111-115.
- 46. Danforth DR, Hodgen GD. "Sunday start" multiphasic oral contraception: ovulation prevention and delayed follicular atresia in primates. *Contraception*. 1989;39(3):321-330.
- 47. Curtis KM, Chrisman CE, Mohllajee AP, Peterson HB. Effective use of hormonal contraceptives: part I: combined oral contraceptive pills. *Contraception*. 2006;73(2):115-124.